=> d his

(FILE 'USPAT' ENTERED AT 11:22:28 ON 09 MAY 1997)

L1 120434 S (TRANSFERRIN(5A) RECEPTOR?) OR TBP? OR TRANSFERRIN?

L2 88 S L1 AND MENINGITIDIS

E MILLET, Q/IN

E QUENTIN-MILLET, /IN

L3 5 S E5-6

=> s (transferrin(5a) receptor?) or tbp? or transferrin?

1453 TRANSFERRIN

26650 RECEPTOR?

236 TRANSFERRIN (5A) RECEPTOR?

1445 TBP?

119073 TRANSFERRIN?

L1 120434 (TRANSFERRIN(5A) RECEPTOR?) OR TBP? OR TRANSFERRIN?

=> s l1 and meningitidis

521 MENINGITIDIS

L2 88 L1 AND MENINGITIDIS

=> d 1-10

- 1. 5,624,802, Apr. 29, 1997, Nucleic acid multimers and amplified nucleic acid hybridization assays using same; Michael S. Urdea, et al., 435/6, 7.1, 810; 436/501; 536/22.1, 23.1, 24.1, 24.3, 24.31, 24.32, 24.33; 935/77, 78 [IMAGE AVAILABLE]
- 2. 5,618,732, Apr. 8, 1997, Method of calibration with photoactivatable chemiluminescent matrices; John S. Pease, et al., 436/8, 172, 905 [IMAGE AVAILABLE]
- 3. 5,618,541, Apr. 8, 1997, Vaccine against Neisseria **meningitidis** infections; Marie-Jose Quentin-Millet, 424/250.1, 249.1; 435/871 [IMAGE AVAILABLE]
- 4. 5,618,540, Apr. 8, 1997, Subunit vaccine against Neisseria
 meningitidis infections and corresponding subunits in the purified
 state; Marie J. Quentin-Millet, et al., 424/250.1, 249.1; 435/871 [IMAGE AVAILABLE]
- 5. 5,614,362, Mar. 25, 1997, Nucleic acid hybridization assay for hepatitis B virus DNA; Michael S. Urdea, et al., 435/5, 6, 243, 320.1, 948; 436/501, 811; 536/23.1, 24.1, 24.3, 24.31, 24.32, 24.33; 935/6, 9, 77, 78 [IMAGE AVAILABLE]
- 6. 5,612,016, Mar. 18, 1997, Conjugates of antibodies and bifunctional ligands; Gary L. Griffiths, et al., 424/1.49, 1.53; 530/391.3, 391.5, 402, 408, 409 [IMAGE AVAILABLE]
- 7. 5,597,572, Jan. 28, 1997, Method of producing Neisseria **meningitidis** B vaccine, and vaccine produced by method; Concepcion C. Huergo, et al., 424/197.11, 250.1, 278.1, 279.1, 282.1; 530/412, 413, 414, 415, 416, 417, 418, 419, 427 [IMAGE AVAILABLE]
- 8. 5,594,118, Jan. 14, 1997, Modified N-4 nucleotides for use in amplified nucleic acid hybridization assays; Michael S. Urdea, et al., 536/23.1; 435/5, 6, 91.1; 536/24.3 [IMAGE AVAILABLE]

- 9. 5,589,335, Dec. 31, 1996, Hybridization promotion reagents; Kevin R. Kearney, et al., 435/6, 967; 935/78, 79 [IMAGE AVAILABLE]
- 10. 5,571,698, Nov. 5, 1996, Directed evolution of novel binding
 proteins; Robert C. Ladner, et al., 435/69.7, 6, 69.1, 172.3, 252.3,
 320.1 [IMAGE AVAILABLE]
 => d 11-20
- 11. 5,571,670, Nov. 5, 1996, Nucleic acid probes useful in detecting Chlamydia trachomatis and amplified nucleic acid hybridization assays using same; Michael S. Urdea, et al., 435/6, 810; 436/501; 536/22.1, 23.1, 24.1, 24.3, 24.31, 24.32, 24.33; 935/77, 78 [IMAGE AVAILABLE]
- 12. 5,556,770, Sep. 17, 1996, Method of preparing a composition that enhances; Renee J. Sugasawara, et al., 435/70.1, 244; 530/350, 413, 417 [IMAGE AVAILABLE]
- 13. 5,545,721, Aug. 13, 1996, Conjugates for the prevention and treatment of sepsis; Sean B. Carroll, et al., 530/391.7, 300, 317, 319, 322, 345, 350, 391.1, 391.5, 391.9, 402 [IMAGE AVAILABLE]
- 14. 5,519,127, May 21, 1996, Nucleic acid probes for the detection of Pneumocystis carinii; Jyotsna Shah, et al., 536/24.32, 23.1, 24.3 [IMAGE AVAILABLE]
- 15. 5,506,139, Apr. 9, 1996, Analog of haemophilus Hin47 with reduced protease activity; Sheena M. Loosmore, et al., 435/252.3, 220, 320.1; 536/23.2, 23.7; 935/10, 14 [IMAGE AVAILABLE]
- 16. 5,494,808, Feb. 27, 1996, Defined medium OMPC fermentation process; Jeffrey Fu, 435/71.1, 101, 252.1, 253.6 [IMAGE AVAILABLE]
- 17. 5,474,769, Dec. 12, 1995, Treatment of microbial infection by monocyte stimulation with interleukin-7; Kenneth Grabstein, et al., 424/85.2; 514/2; 530/351 [IMAGE AVAILABLE]
- 18. 5,468,485, Nov. 21, 1995, Avirulent microbes and uses therefor; Roy Curtiss, III, 424/184.1, 93.1, 93.2, 200.1; 435/69.1, 71.1, 172.1, 252.3, 252.33, 252.8 [IMAGE AVAILABLE]
- 19. 5,424,065, Jun. 13, 1995, Vaccines containing avirulent phop-type microorganisms; Roy Curtiss, III, et al., 424/93.2, 93.48, 184.1; 435/69.1, 71.1, 252.3, 252.8 [IMAGE AVAILABLE]
- 20. 5,407,609, Apr. 18, 1995, Microencapsulation process and products therefrom; Thomas R. Tice, et al., 264/4.6, 4.1; 427/213.3, 213.36 [IMAGE

AVAILABLE] => d 21-40

- 21. 5,403,718, Apr. 4, 1995, Methods and antibodies for the immune capture and detection of Borrelia burgdorferi; David W. Dorward, et al., 435/7.32, 7.94; 530/387.1, 388.4, 389.5 [IMAGE AVAILABLE]
- 22. 5,403,484, Apr. 4, 1995, Viruses expressing chimeric binding proteins; Robert C. Ladner, et al., 435/235.1, 69.7, 172.3, 252.3, 320.1; 530/350; 536/23.4 [IMAGE AVAILABLE]
- 23. 5,389,368, Feb. 14, 1995, Avirulent microbes and uses therefor; Roy Gurtiss, III, 424/93.2, 93.4; 435/172.3, 320.1; 935/72, 73 [IMAGE AVAILABLE]
- 24. 5,387,744, Feb. 7, 1995, Avirulent microbes and uses therefor: Salmonella typhi; Roy Curtiss, III, et al., 424/235.1, 258.1; 435/172.3, 252.3, 252.33, 320.1, 879; 935/60, 62, 72 [IMAGE AVAILABLE]
- 25. 5,359,100, Oct. 25, 1994, Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers; Michael S. Urdea, et al., 552/105; 549/220; 558/185 [IMAGE AVAILABLE]
- 26. 5,340,716, Aug. 23, 1994, Assay method utilizing photoactivated chemiluminescent label; Edwin F. Ullman, et al., 435/6, 7.7 [IMAGE AVAILABLE]
- 27. 5,334,379, Aug. 2, 1994, Cytokine and hormone carriers for conjugate vaccines; Subramonia Pillai, et al., 424/85.2, 85.1, 85.4, 197.11, 244.1, 250.1, 831; 530/351, 395, 404, 405, 406, 411 [IMAGE AVAILABLE]
- 28. 5,314,811, May 24, 1994, Process for converting lipid-containing bacterial capsular polysaccharide into lipid-free polysaccharide; Ann L. Lee, et al., 435/101; 210/601, 616, 631; 424/256.1, 831; 435/170, 262, 280; 536/117, 123.1 [IMAGE AVAILABLE]
- 29. 5,294,441, Mar. 15, 1994, Avirulent microbes and uses therefor: salmonella typhi; Roy Curtiss, III, 424/200.1, 235.1, 258.1; 435/172.3, 252.3, 252.33, 320.1, 879; 935/60, 62, 72 [IMAGE AVAILABLE]
- 30. 5,292,869, Mar. 8, 1994, Method for isolating and purifying **transferrin** and lactoferrin **receptor** proteins from bacteria and the preparation of vaccines containing the same; Anthony B. Schryvers, 530/413; 424/234.1, 249.1, 250.1, 255.1, 256.1; 530/350, 380, 394, 395, 400, 412, 417 [IMAGE AVAILABLE]
- 31. 5,254,339, Oct. 19, 1993, Process for preparing immune complexes;

Bror Morein, 424/191.1, 193.1, 195.11, 196.11, 197.11; 514/2, 8 [IMAGE AVAILABLE]

- 32. 5,223,409, Jun. 29, 1993, Directed evolution of novel binding proteins; Robert C. Ladner, et al., 435/69.7, 5, 69.1, 172.3, 252.3, 320.1; 530/387.3, 387.5 [IMAGE AVAILABLE]
- 33. 5,202,232, Apr. 13, 1993, IgA binding protein; Milan Blake, et al., 435/7.1; 530/350, 387.1, 413 [IMAGE AVAILABLE]
- 34. 5,169,599, Dec. 8, 1992, Method and apparatus for optically detecting presence of immunological components; Jose P. Joseph, et al., 422/57; 436/525, 808, 810 [IMAGE AVAILABLE]
- 35. 5,141,743, Aug. 25, 1992, Method for isolating and purifying **transferrin** and lactoferrin **receptor** proteins and vaccines containing the same; Anthony B. Schryvers, 424/234.1, 249.1, 250.1, 255.1, 256.1, 278.1; 530/350, 395, 400, 413 [IMAGE AVAILABLE]
- 36. 5,124,246, Jun. 23, 1992, Nucleic acid multimers and amplified nucleic acid hybridization assays using same; Michael S. Urdea, et al., 435/6, 810; 436/501; 536/23.1, 24.3, 24.31, 24.32; 935/23, 78, 88 [IMAGE AVAILABLE]
- 37. 5,030,556, Jul. 9, 1991, Species-specific DNNA probe for the detection of Branhamella catarrhalis; Danielle Beaulieu, et al., 435/6, 4, 29; 436/94, 501 [IMAGE AVAILABLE]
- 38. 4,971,900, Nov. 20, 1990, Method for the detection of biologically active agents; Joseph E. Ahnell, et al., 435/29, 34, 287.5, 807; 436/146 [IMAGE AVAILABLE]
- 39. 4,888,170, Dec. 19, 1989, Vaccines obtained from antigenic gene products of recombinant genes; Roy Curtiss, III, 424/200.1, 244.1, 258.1; 435/252.3, 252.8 [IMAGE AVAILABLE]
- 40. 4,808,700, Feb. 28, 1989, Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers; Porter W. Anderson, et al., 424/194.1, 197.11, 241.1, 256.1, 831; 435/6, 172.3; 514/12; 530/403, 807, 808, 812; 935/12 [IMAGE AVAILABLE] => d 41-60
- 41. 4,774,191, Sep. 27, 1988, Fluorescent conjugates bound to a support; Pyare Khanna, et al., 436/518, 528, 529, 546, 800, 805 [IMAGE AVAILABLE]
- 42. 4,757,134, Jul. 12, 1988, IgA binding protein; Milan Blake, et al., 530/350; 435/71.2, 72, 84, 101, 885; 436/513; 530/412, 413, 418, 419,

- 422, 424, 825, 861; 536/124; 930/200 [IMAGE AVAILABLE]
- 43. 4,755,459, Jul. 5, 1988, Detection of gonococcal infections using monoclonal antibodies; Terry W. Pearson, et al., 435/7.36, 34, 35, 39, 188, 871; 436/545, 546, 811; 530/388.4, 391.3 [IMAGE AVAILABLE]
- 44. 4,744,983, May 17, 1988, Immunogenic protein or peptide complex, method of producing said complex and the use thereof as an immune stimulant and as a vaccine; Bror Morein, 424/196.11, 193.1, 197.11, 209.1, 211.1, 212.1, 216.1, 217.1, 218.1, 224.1, 227.1, 250.1, 257.1, 258.1, 273.1, 278.1; 435/69.3, 70.3, 71.2, 172.2, 172.3; 530/300, 344, 350, 403, 406, 419, 423 [IMAGE AVAILABLE]
- 45. 4,717,660, Jan. 5, 1988, Detection of bacteria by fluorescent staining in an expanded buffy coat; Thomas H. Schulte, 435/30, 29, 34 [IMAGE AVAILABLE]
- 46. 4,681,762, Jul. 21, 1987, Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype; Max P. Oeschger, et al., 424/256.1, 830; 435/172.1, 172.3, 245 [IMAGE AVAILABLE]
- 47. 4,652,531, Mar. 24, 1987, Fluorescent protein binding assays with unsymmetrical fluorescein derivatives; Pyare Khanna, et al., 436/501, 518, 537, 546, 800 [IMAGE AVAILABLE]
- 48. 4,650,770, Mar. 17, 1987, Energy absorbing particle quenching in light emitting competitive protein binding assays; Yen-Ping Liu, et al., 436/523, 533, 534, 537, 546, 805 [IMAGE AVAILABLE]
- 49. 4,588,697, May 13, 1986, Method for performing fluorescent protein binding assay employing novel alkyl substituted fluorescent compounds and conjugates; Pyare Khanna, et al., 436/518, 528, 531, 532, 537, 546, 800; 530/406, 807 [IMAGE AVAILABLE]
- 50. 4,578,269, Mar. 25, 1986, Immunogenic protein or peptide complex, method or producing said complex and the use thereof as an immune stimulant and as a vaccine; Bror Morein, 424/196.11, 193.1, 197.11, 207.1, 209.1, 211.1, 212.1, 216.1, 217.1, 218.1, 224.1, 227.1, 250.1, 257.1, 258.1, 273.1; 530/350, 806 [IMAGE AVAILABLE]
- 51. 4,501,692, Feb. 26, 1985, Charge effects in enzyme immunoassays; Ian Gibbons, et al., 530/391.5; 424/530; 435/188; 436/547; 530/389.3 [IMAGE AVAILABLE]
- 52. 4,481,136, Nov. 6, 1984, Alkyl substituted fluorescent compounds and conjugates; Pyare Khanna, et al., 530/391.5; 435/177, 178, 188, 968; 436/546, 547; 525/420; 530/363, 403, 404, 405, 406, 802, 806; 549/388

[IMAGE AVAILABLE]

- 53. 4,439,356, Mar. 27, 1984, Unsymmetrical fluorescein derivatives;
 Pyare Khanna, et al., 530/350; 435/5, 7.31, 7.32, 7.33, 7.34, 7.35, 7.36,
 7.37, 188, 961; 436/172, 546; 525/420; 530/391.5, 406 [IMAGE AVAILABLE]
- 54. 4,391,904, Jul. 5, 1983, Test strip kits in immunoassays and compositions therein; David J. Litman, et al., 435/7.91; 422/55, 56; 435/188, 805, 810, 975; 436/536, 537 [IMAGE AVAILABLE]
- 55. 4,374,925, Feb. 22, 1983, Macromolecular environment control in specific receptor assays; David J. Litman, et al., 435/7.91, 5, 7.31, 7.32, 7.33, 7.34, 7.35, 7.36, 7.37, 7.8, 7.92, 177, 810, 966, 968, 971; 436/529, 800 [IMAGE AVAILABLE]
- 56. 4,366,241, Dec. 28, 1982, Concentrating zone method in heterogeneous immunoassays; Henry K. Tom, et al., 435/7.91; 422/56; 435/5, 7.9, 7.92, 805, 810, 968, 975; 436/541, 800, 807 [IMAGE AVAILABLE]
- 57. 4,351,760, Sep. 28, 1982, Novel alkyl substituted fluorescent compounds and polyamino acid conjugates; Pyare Khanna, et al., 530/395; 435/7.2, 188, 961, 968; 436/546, 547; 530/345, 391.5, 405, 406, 806; 549/388 [IMAGE AVAILABLE]
- 58. 4,337,314, Jun. 29, 1982, Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype; Max P. Oeschger, et al., 435/252.3; 424/256.1, 830; 435/172.1, 851 [IMAGE AVAILABLE]
- 59. 4,328,311, May 4, 1982, Enzyme-aminoglycoside conjugates; Gerald L. Rowley, et al., 435/188, 177; 530/345, 375, 391.9, 405, 406, 408, 806 [IMAGE AVAILABLE]
- 60. 4,318,846, Mar. 9, 1982, Novel ether substituted fluorescein polyamino acid compounds as fluorescers and quenchers; Pyare Khanna, et al., 530/391.5; 435/188, 961, 968; 436/546, 547; 525/420; 530/345, 389.3, 391.3, 404, 405, 406, 409, 410, 806; 549/223, 388 [IMAGE AVAILABLE] => d 61-80
- 61. 4,299,916, Nov. 10, 1981, Preferential signal production on a surface in immunoassays; David J. Litman, et al., 435/6; 422/56; 435/7.4, 7.91, 805, 810, 975; 436/544, 547, 800, 805, 806, 808, 811, 815, 820, 826 [IMAGE AVAILABLE]
- 62. 4,287,300, Sep. 1, 1981, Charge effects in enzyme immunoassays; Ian Gibbons, et al., 435/5, 7.32, 7.9, 188, 810; 436/527, 529, 531, 546, 547, 800, 805, 806, 811, 815, 820 [IMAGE AVAILABLE]

- 63. 4,281,061, Jul. 28, 1981, Double antibody for enhanced sensitivity in immunoassay; Robert F. Zuk, et al., 435/7.9, 5, 7.2, 7.31, 7.32, 7.33, 7.34, 7.35, 7.36, 7.37, 7.7, 7.8, 7.91, 188, 966, 968, 971; 436/537, 540, 800, 808 [IMAGE AVAILABLE]
- 64. 4,277,437, Jul. 7, 1981, Kit for carrying out chemically induced fluorescence immunoassay; Edward T. Maggio, 422/61; 180/65.8; 435/8, 810, 968, 975; 436/513, 537, 800, 808, 811, 815, 820 [IMAGE AVAILABLE]
- 65. 4,275,149, Jun. 23, 1981, Macromolecular environment control in specific receptor assays; David J. Litman, et al., 435/7.91, 5, 6, 7.1, 7.2, 7.31, 7.32, 7.33, 7.34, 7.35, 7.36, 7.37, 7.71, 7.72, 7.8, 7.92, 177, 178, 810, 968, 971; 436/531 [IMAGE AVAILABLE]
- 66. 4,272,506, Jun. 9, 1981, Purification of reagents by disulfide immobilization; Moshe Schwarzberg, 436/512; 250/302; 435/4, 962, 964, 968; 436/513, 546, 547, 800, 825; 530/389.1, 389.3, 391.1, 391.3, 404, 413, 813, 861 [IMAGE AVAILABLE]
- 67. 4,264,766, Apr. 28, 1981, Immunological diagnostic reagents; Ernst A. Fischer, 524/556; 424/534, 545; 436/529, 533, 823; 525/54.2; 530/389.3, 391.1, 403, 815; 536/30, 45, 46, 47, 56, 102, 103, 112 [IMAGE AVAILABLE]
- 68. 4,261,968, Apr. 14, 1981, Fluorescence quenching with immunological pairs in immunoassays; Edwin F. Ullman, et al., 436/546; 250/302; 435/968; 436/530, 537, 547, 800, 811, 815, 816, 820, 826 [IMAGE AVAILABLE]
- 69. 4,260,683, Apr. 7, 1981, Process for producing antibacterial agents; Hiroshi Kawaguchi, et al., 435/74 [IMAGE AVAILABLE]
- 70. 4,256,834, Mar. 17, 1981, Fluorescent scavenger particle immunoassay; Robert F. Zuk, et al., 435/7.72, 5, 7.2, 7.32, 7.4, 810, 975; 436/529, 534, 537, 800, 805, 808 [IMAGE AVAILABLE]
- 71. 4,250,170, Feb. 10, 1981, Antibacterial agents Bu-2349A and B and method of using same; Hiroshi Kawaguchi, et al., 514/61; 435/80; 536/16.8 [IMAGE AVAILABLE]
- 72. 4,240,751, Dec. 23, 1980, Method and apparatus for specific binding substances; Carl B. Linnecke, et al., 356/409; 250/227.11, 526; 356/246, 440; 422/82.05, 102, 942; 435/288.4, 288.7, 808 [IMAGE AVAILABLE]
- 73. 4,235,869, Nov. 25, 1980, Assay employing a labeled Fab-fragment ligand complex; Moshe Schwarzberg, 436/512; 250/302; 435/7.7, 7.72, 968; 436/513, 536, 537, 541, 800 [IMAGE AVAILABLE]

- 74. 4,233,402, Nov. 11, 1980, Reagents and method employing channeling; Edward T. Maggio, et al., 435/5, 7.7, 7.91, 968; 436/537, 805 [IMAGE AVAILABLE]
- 75. 4,233,401, Nov. 11, 1980, Antienzyme homogeneous competitive binding assay; Robert A. Yoshida, et al., 435/7.8, 7.9, 185, 810, 963 [IMAGE AVAILABLE]
- 76. 4,220,722, Sep. 2, 1980, Method for conjugating to polyamino compounds employing haloacyl groups and compositions prepared thereby; Gerald L. Rowley, et al., 435/188, 7.9, 177, 961, 964; 436/537, 816, 823; 530/322, 345, 395, 403, 404, 405, 406, 408, 409, 410, 806 [IMAGE AVAILABLE]
- 77. 4,220,450, Sep. 2, 1980, Chemically induced fluorescence immunoassay; Edward T. Maggio, 436/537; 435/5, 7.32, 7.5, 7.71, 7.8, 7.9, 8, 966, 968; 436/500, 800, 816, 817 [IMAGE AVAILABLE]
- 78. 4,208,479, Jun. 17, 1980, Label modified immunoassays; Robert F. Zuk, et al., 435/7.9, 7.72, 7.8; 436/512, 537, 808, 826 [IMAGE AVAILABLE]
- 79. 4,199,559, Apr. 22, 1980, Fluorescence quenching with immunological pairs in immunoassays; Edwin F. Ullman, et al., 436/537, 800, 816 [IMAGE AVAILABLE]
- 80. 4,198,389, Apr. 15, 1980, Determination of immunologically active materials and system therefore; Charles Wadsworth, 436/513; 422/56; 436/516, 806, 807 [IMAGE AVAILABLE] => d his
 - (FILE 'USPAT' ENTERED AT 11:22:28 ON 09 MAY 1997)
- L1 120434 S (TRANSFERRIN(5A) RECEPTOR?) OR TBP? OR TRANSFERRIN?
- L2 88 S L1 AND MENINGITIDIS
- => d 81-88
- 81. 4,193,983, Mar. 18, 1980, Labeled liposome particle compositions and immunoassays therewith; Edwin F. Ullman, et al., 436/528; 424/450; 435/7.7, 7.72, 7.9, 7.91, 188, 961, 968; 436/535, 537, 815, 819, 829; 530/359, 389.1, 389.2, 389.3, 389.5, 389.8 [IMAGE AVAILABLE]
- 82. 4,181,636, Jan. 1, 1980, Process for producing immunological diagnostic reagents; Ernst A. Fischer, 525/54.1; 435/181; 436/823; 525/54.2 [IMAGE AVAILABLE]
- 83. 4,174,384, Nov. 13, 1979, Fluorescence quenching with immunological pairs in immunoassays; Edwin F. Ullman, et al., 436/537; 250/302; 435/7.1, 7.2, 7.31, 7.32, 7.8, 968; 436/800, 816; 530/363, 389.3, 389.8,

- 84. 4,160,645, Jul. 10, 1979, Catalyst mediated competitive protein binding assay; Edwin F. Ullman, 436/517, 537, 803, 805, 806, 816 [IMAGE AVAILABLE]
- 85. 4,104,127, Aug. 1, 1978, Article for growing cultures in a body cavity in the presence of gas, and package for the article; Louis Bucalo, 128/769, 749; 435/34, 36, 37, 810; 604/385.1 [IMAGE AVAILABLE]
- 86. 4,067,776, Jan. 10, 1978, Method for differential diagnosis of meningitis with a limulus lysate test; Waheed N. Khan, 435/34, 183, 212, 852, 947 [IMAGE AVAILABLE]
- 87. 3,996,345, Dec. 7, 1976, Fluorescence quenching with immunological pairs in immunoassays; Edwin F. Ullman, et al., 436/537; 252/301.16; 435/5, 7.1, 7.2, 7.4, 968; 436/800, 815, 816, 817; 530/363, 389.3, 389.8, 391.3, 404, 406, 408, 410 [IMAGE AVAILABLE]
- 88. 3,979,263, Sep. 7, 1976, Method for growing cultures in a body cavity in the presence of gas; Louis Bucalo, 435/34; 128/749; 435/36, 37, 299.1, 309.1; 604/55, 57 [IMAGE AVAILABLE] => e millet. g/in

=> e	miller,	d/ 111			
E#	FILE	FREQUENCY	TERM		
E1	USPAT	1	MILLET, PASCAL/IN		
E2	USPAT	3	MILLET, PIERRE/IN		
E3	USPAT	0>	MILLET, Q/IN		
E4	USPAT	2	MILLET, SERGE D/IN		
E5	USPAT	1	MILLET, STEPHANE/IN		
E6	USPAT	1	MILLET, TERRANCE/IN		
E7	USPAT	1	MILLET, WILLIAM G/IN		
E8	USPAT	2	MILLET, YVES/IN		
E9	USPAT	3	MILLET, YVON/IN		
E10	USPAT	1	MILLETICS, MICHAEL L/IN		
E11	USPAT	1	MILLETT, BRADBURNE L/IN		
E12	USPAT	3	MILLETT, CLAUDE R/IN		
=> e quentin-millet, /in					
E#	FILE	FREQUENCY	TERM		
E1	USPAT	1	QUENOUILLE, GEORGES EMILE/IN		
E2	USPAT	1	QUENTER, HORST/IN		
E3	USPAT	0>	QUENTIN MILLET,/IN		
E4	USPAT	1	QUENTIN MILLET, MARIE J/IN		
E5	USPAT	2	QUENTIN MILLET, MARIE JOSE/IN		
E6	~USPAT	. 3	QUENTIN MILLET, MARIE JOSE B/IN		
E7	USPAT	1	QUENTIN, ERIC/IN		

E8	USPAT	1	QUENTIN, ERIC	P F/IN
E9	USPAT	1	QUENTIN, GEOR	RGE H/IN
E10	USPAT	1	QUENTIN, GERA	AD/IN
E11	USPAT	3	QUENTIN, GERA	ARD/IN
E12	USPAT	1	QUENTIN, GERA	ARD J/IN
=> S	e5-6			

2 "QUENTIN MILLET, MARIE JOSE"/IN

3 "QUENTIN MILLET, MARIE JOSE B"/IN

L3 5 ("QUENTIN MILLET, MARIE JOSE"/IN OR "QUENTIN MILLET, MARIE JOS

E B"/IN)

=> d 1-5

- 1. 5,618,541, Apr. 8, 1997, Vaccine against Neisseria meningitidis infections; **Marie-Jose Quentin-Millet**, 424/250.1, 249.1; 435/871 [IMAGE AVAILABLE]
- 2. 5,045,203, Sep. 3, 1991, Separation of protein antigens of Bordetella bacteria by affinity chromatography; **Marie-Jose Quentin-Millet**, et al., 210/635, 198.2, 502.1, 656; 502/403; 530/413, 417, 825 [IMAGE AVAILABLE]
- 3. 4,985,144, Jan. 15, 1991, Affinity chromatography material for antigens of the bacteria of the Bordetella genus; **Marie-Jose B. Quentin-Millet**, et al., 210/198.2, 502.1, 635, 656; 502/403; 530/413, 417 [IMAGE AVAILABLE]
- 4. 4,965,205, Oct. 23, 1990, Culture medium for bacteria of the bordetella genus containing etherified derivative of D-glucose and a cyclodextrin; **Marie-Jose B. Quentin-Millet**, et al., 435/252, 244, 248, 252.1, 253.6, 822 [IMAGE AVAILABLE]
- 5. 4,774,086, Sep. 27, 1988, Process for the purification, solubilization and/or detoxification of protein antigens of bacteria of the Bordetella genus using a carbonate buffer and an acellular anti-whooping cough vaccine; **Marie-Jose B. Quentin-Millet**, et al., 424/240.1, 254.1, 278.1; 435/243, 244, 822; 530/417 [IMAGE AVAILABLE]